Bactiguard Holding AB (publ) announced strengthened ties with Becton Dickinson & Company (BD), Bactiguard?s longest and strongest license collaboration. An interim agreement has been signed granting BD an exclusive global license, effective immediately, for Bactiguard coated Foley catheters,which is a first step on the strategy of phasing-out Bactiguard?s medical device portfolio. As communicated earlier this year, Bactiguard has sharpened its strategy to focus fully on the licensing business and transform from a medical device production company to a knowledge and specialist organization.

An important part of the transformation is the phase-out of Bactiguard?s medical device portfolio. The interim agreement to extend the partnership with BD includes sales exclusivity of Foleys not only in the US, Japan, UK, Canada, Ireland, and Australia, but now also the rest of the world (excluding China) and aims at limiting supply disruptions for current distributors and customers. The majority will be offered Bactiguard coated BD Foley catheters which have similar features and functionality to the Bactiguard Foley.

It is both parties? expectations to enter into an expanded long-term license agreement during the first half of 2024.